Valuation: Femasys Inc.

Market Cap 10.87M 9.53M 8.79M 8.23M 15.42M 1.03B 15.74M 106M 40.86M 507M 40.82M 39.93M 1.76B P/E 2026 *
-0.79x
P/E 2027 * -0.66x
Enterprise Value 10.87M 9.53M 8.79M 8.23M 15.42M 1.03B 15.74M 106M 40.86M 507M 40.82M 39.93M 1.76B EV / Sales 2026 *
2.89x
EV / Sales 2027 * 1.09x
Free-Float
90.43%
Yield 2026 *
-
Yield 2027 * -
1 day+6.53%
1 week-6.37%
Current month-50.65%
1 month-53.41%
3 months-61.65%
6 months-73.10%
Current year-66.85%
1 week 3.5
Extreme 3.5
4.45
1 month 3.5
Extreme 3.5
7.8
Current year 3.5
Extreme 3.5
14.51
1 year 3.5
Extreme 3.5
22.2
3 years 3.5
Extreme 3.5
95
5 years 3.5
Extreme 3.5
215.8
10 years 3.5
Extreme 3.5
275
Manager TitleAgeSince
Chief Executive Officer 59 2003-12-31
Director of Finance/CFO 58 2022-02-27
Chief Operating Officer 52 2026-03-29
Director TitleAgeSince
Chairman 59 2003-12-31
Chairman 74 2022-07-05
Director/Board Member 75 2005-07-31
Date Insider Type Main position Quantity % Market Cap.
03-29Other

Chief Operating Officer

30,000 0.0504%
03-29Free

Chief Operating Officer

150,000 0.2521%
03-18Free

Chairman

34,122 0.0573%
Change 5-day change 1-year change 3-year change Capi.($)
+6.53%-6.37%-80.57%-70.60% 10.87M
+1.10%+7.49%-29.37%-12.99% 162B
+1.34%+2.11%-6.08%-6.97% 103B
+0.58%+6.26%-2.81%+53.52% 55.83B
-2.09%-10.31%+49.00%+52.19% 54.05B
+2.42%+10.23%-8.75%-39.53% 41.71B
+2.66%+11.64% - - 31.94B
+0.98%+0.27%-18.56%-44.43% 26.49B
-0.19%+5.02%+58.10%-5.16% 24.48B
+2.26%+7.39%-9.78%+1.51% 20.52B
Average +1.56%+0.44%-5.42%-8.05% 52.05B
Weighted average by Cap. +0.94%+2.27%-5.20%+0.12%

Financials

2026 *2027 *
Net sales 3.77M 3.3M 3.04M 2.85M 5.34M 355M 5.45M 36.59M 14.16M 176M 14.14M 13.83M 609M 10M 8.77M 8.08M 7.57M 14.19M 944M 14.49M 97.16M 37.6M 466M 37.56M 36.74M 1.62B
Net income -16.22M -14.22M -13.11M -12.27M -23.01M -1.53B -23.49M -158M -60.96M -756M -60.9M -59.57M -2.62B -21.29M -18.66M -17.2M -16.11M -30.2M -2.01B -30.83M -207M -80.01M -992M -79.93M -78.18M -3.44B
Net Debt - -
Logo Femasys Inc.
Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
Employees
53
Date Price Change Volume
26-06-26 US$3.820 +6.11% 31,599
26-06-25 US$3.600 -1.91% 48,839
26-06-24 US$3.670 -8.48% 49,200
26-06-23 US$4.010 -1.72% 14,607
26-06-22 US$4.080 +0.99% 43,979
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.600USD
Average target price
63.33USD
Spread / Average Target
+1,659.26%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FEMY Stock